ALNY vs. CAH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALNY and CAH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ALNY’s market capitalization stands at 43.28 billion USD, while CAH’s is 39.36 billion USD, indicating their market valuations are broadly comparable.
CAH carries a higher beta at 0.68, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.
| Symbol | ALNY | CAH |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Cardinal Health, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Distribution |
| CEO | Yvonne L. Greenstreet | Jason M. Hollar |
| Price | 331.91 USD | 164.93 USD |
| Market Cap | 43.28 billion USD | 39.36 billion USD |
| Beta | 0.21 | 0.68 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | August 4, 1983 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ALNY and CAH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALNY
-509.33%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
CAH
-50.14%
Medical - Distribution Industry
- Max
- 12.20%
- Q3
- 12.03%
- Median
- -50.14%
- Q1
- -62.68%
- Min
- -132.73%
CAH has a negative Return on Equity of -50.14%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Return on Invested Capital
ALNY
-2.79%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
CAH
12.79%
Medical - Distribution Industry
- Max
- 26.59%
- Q3
- 11.51%
- Median
- 7.70%
- Q1
- -0.02%
- Min
- -5.86%
In the upper quartile for the Medical - Distribution industry, CAH’s Return on Invested Capital of 12.79% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ALNY
-11.49%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
CAH
0.70%
Medical - Distribution Industry
- Max
- 3.21%
- Q3
- 2.07%
- Median
- 0.70%
- Q1
- -1.43%
- Min
- -6.29%
CAH’s Net Profit Margin of 0.70% is aligned with the median group of its peers in the Medical - Distribution industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ALNY
-4.91%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
CAH
1.07%
Medical - Distribution Industry
- Max
- 5.22%
- Q3
- 3.23%
- Median
- 1.07%
- Q1
- -0.39%
- Min
- -4.51%
CAH’s Operating Profit Margin of 1.07% is around the midpoint for the Medical - Distribution industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ALNY | CAH |
|---|---|---|
| Return on Equity (TTM) | -509.33% | -50.14% |
| Return on Assets (TTM) | -6.40% | 3.12% |
| Return on Invested Capital (TTM) | -2.79% | 12.79% |
| Net Profit Margin (TTM) | -11.49% | 0.70% |
| Operating Profit Margin (TTM) | -4.91% | 1.07% |
| Gross Profit Margin (TTM) | 86.01% | 3.50% |
Financial Strength
Current Ratio
ALNY
3.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
CAH
0.94
Medical - Distribution Industry
- Max
- 1.38
- Q3
- 1.26
- Median
- 1.13
- Q1
- 0.92
- Min
- 0.87
CAH’s Current Ratio of 0.94 aligns with the median group of the Medical - Distribution industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ALNY
11.28
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
CAH
-2.60
Medical - Distribution Industry
- Max
- 0.97
- Q3
- 0.97
- Median
- 0.65
- Q1
- 0.04
- Min
- 0.03
CAH has a Debt-to-Equity Ratio of -2.60, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.
Interest Coverage Ratio
ALNY
-0.79
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
CAH
15.45
Medical - Distribution Industry
- Max
- 25.45
- Q3
- 12.43
- Median
- 7.07
- Q1
- 1.82
- Min
- -1.21
CAH’s Interest Coverage Ratio of 15.45 is in the upper quartile for the Medical - Distribution industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | ALNY | CAH |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 0.94 |
| Quick Ratio (TTM) | 2.98 | 0.50 |
| Debt-to-Equity Ratio (TTM) | 11.28 | -2.60 |
| Debt-to-Asset Ratio (TTM) | 0.31 | 0.15 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.85 | 1.55 |
| Interest Coverage Ratio (TTM) | -0.79 | 15.45 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALNY and CAH. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
CAH
1.23%
Medical - Distribution Industry
- Max
- 1.21%
- Q3
- 0.56%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CAH’s Dividend Yield of 1.23% is exceptionally high, placing it well above the typical range for the Medical - Distribution industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
CAH
31.84%
Medical - Distribution Industry
- Max
- 31.84%
- Q3
- 21.47%
- Median
- 5.24%
- Q1
- 0.00%
- Min
- 0.00%
CAH’s Dividend Payout Ratio of 31.84% is in the upper quartile for the Medical - Distribution industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | ALNY | CAH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.23% |
| Dividend Payout Ratio (TTM) | 0.00% | 31.84% |
Valuation
Price-to-Earnings Ratio
ALNY
-159.59
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
CAH
25.41
Medical - Distribution Industry
- Max
- 34.27
- Q3
- 27.58
- Median
- 25.75
- Q1
- 22.28
- Min
- 18.73
CAH’s P/E Ratio of 25.41 is within the middle range for the Medical - Distribution industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ALNY
-43.29
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
CAH
1.88
Medical - Distribution Industry
- Max
- 3.40
- Q3
- 2.79
- Median
- 2.36
- Q1
- 2.08
- Min
- 1.94
CAH’s Forward PEG Ratio of 1.88 is below the typical range for the Medical - Distribution industry. This is a strong indicator that the stock may be undervalued, as its price appears low given its future growth prospects.
Price-to-Sales Ratio
ALNY
18.43
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
CAH
0.18
Medical - Distribution Industry
- Max
- 1.08
- Q3
- 0.89
- Median
- 0.25
- Q1
- 0.18
- Min
- 0.06
In the lower quartile for the Medical - Distribution industry, CAH’s P/S Ratio of 0.18 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio
ALNY
372.86
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
CAH
-13.43
Medical - Distribution Industry
- Max
- 8.13
- Q3
- 8.13
- Median
- 2.74
- Q1
- 2.19
- Min
- 1.20
CAH has a negative P/B Ratio of -13.43, indicating its liabilities exceed its assets and result in negative shareholder equity. This is a critical warning sign of financial distress.
Valuation at a Glance
| Symbol | ALNY | CAH |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -159.59 | 25.41 |
| Forward PEG Ratio (TTM) | -43.29 | 1.88 |
| Price-to-Sales Ratio (P/S, TTM) | 18.43 | 0.18 |
| Price-to-Book Ratio (P/B, TTM) | 372.86 | -13.43 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -574.08 | 16.14 |
| EV-to-EBITDA (TTM) | -285.32 | 15.54 |
| EV-to-Sales (TTM) | 18.55 | 0.20 |